
1. genes (basel). 2019 jun 21;10(6). pii: e471. doi: 10.3390/genes10060471.

identification plasmodium falciparum mitochondrial malate: quinone
oxidoreductase inhibitors pathogen box.

wang x(1)(2), miyazaki y(3), inaoka dk(4)(5)(6), hartuti ed(7), watanabe yi(8),
shiba t(9), harada s(10), saimoto h(11), burrows jn(12), benito fjg(13), nozaki
t(14), kita k(15)(16)(17).

author information: 
(1)department biomedical chemistry, graduate school medicine, the
university tokyo, 7-3-1, hongo, bunkyo-ku, tokyo 113-0033, japan.
xinying-wang@nagasaki-u.ac.jp.
(2)school tropical medicine global health, nagasaki university, 1-12-4,
sakamoto, nagasaki 852-8523, japan. xinying-wang@nagasaki-u.ac.jp.
(3)graduate school biomedical sciences, nagasaki university, 1-12-4, sakamoto,
nagasaki 852-8523, japan. y.miyazaki@lumc.nl.
(4)department biomedical chemistry, graduate school medicine, the
university tokyo, 7-3-1, hongo, bunkyo-ku, tokyo 113-0033, japan.
danielken@nagasaki-u.ac.jp.
(5)school tropical medicine global health, nagasaki university, 1-12-4,
sakamoto, nagasaki 852-8523, japan. danielken@nagasaki-u.ac.jp.
(6)department molecular infection dynamics, institute tropical medicine
(nekken), nagasaki university, 1-12-4, sakamoto, nagasaki 852-8523, japan.
danielken@nagasaki-u.ac.jp.
(7)graduate school biomedical sciences, nagasaki university, 1-12-4, sakamoto,
nagasaki 852-8523, japan. endah.dwi08@yahoo.co.id.
(8)department biomedical chemistry, graduate school medicine, the
university tokyo, 7-3-1, hongo, bunkyo-ku, tokyo 113-0033, japan.
ywatanab@m.u-tokyo.ac.jp.
(9)department applied biology, graduate school science technology, kyoto
institute technology, matsugasaki, hashikamicho, sakyo-ku, kyoto 606-8585,
japan. tshiba@kit.ac.jp.
(10)department applied biology, graduate school science technology, kyoto
institute technology, matsugasaki, hashikamicho, sakyo-ku, kyoto 606-8585,
japan. harada@kit.ac.jp.
(11)department chemistry biotechnology, graduate school engineering,
tottori university, 4-101 koyama-cho minami, tottori 680-8550, japan.
saimoto@chem.tottori-u.ac.jp.
(12)medicines malaria venture, route de pré bois 20, 1215 geneva,
switzerland. burrowsj@mmv.org.
(13)glaxosmithkline (gsk), tres cantos medicine development campus, severo ochoa,
28760 madrid, spain. francisco-javier.b.gamo@gsk.com.
(14)department biomedical chemistry, graduate school medicine, the
university tokyo, 7-3-1, hongo, bunkyo-ku, tokyo 113-0033, japan.
nozaki@m.u-tokyo.ac.jp.
(15)department biomedical chemistry, graduate school medicine, the
university tokyo, 7-3-1, hongo, bunkyo-ku, tokyo 113-0033, japan.
kitak@nagasaki-u.ac.jp.
(16)school tropical medicine global health, nagasaki university, 1-12-4,
sakamoto, nagasaki 852-8523, japan. kitak@nagasaki-u.ac.jp.
(17)department host-defense biochemistry, institute tropical medicine
(nekken), nagasaki university, 1-12-4, sakamoto, nagasaki 852-8523, japan.
kitak@nagasaki-u.ac.jp.

malaria one three major global health threats. drug development for
malaria, especially dangerous form caused plasmodium falciparum, 
remains urgent task due emerging drug-resistant parasites. exploration 
of novel antimalarial drug targets identified trifunctional enzyme, malate
quinone oxidoreductase (mqo), located mitochondrial inner membrane p.
falciparum (pfmqo). pfmqo involved pathways mitochondrial electron
transport chain, tricarboxylic acid cycle, fumarate cycle. recent studies
have shown mqo essential p. falciparum survival asexual stage 
for development experiment cerebral malaria murine parasite p.
berghei, providing genetic validation mqo drug target. however, chemical 
validation mqo, target, remains unexplored. study, used active
recombinant protein rpfmqo overexpressed bacterial membrane fractions to
screen total 400 compounds pathogen box, released medicines 
malaria venture. screening identified seven hit compounds targeting rpfmqo
with ic50 5 μm. tested activity hit compounds the
growth 3d7 wildtype strain p. falciparum, among four compounds showed
an ic50 low sub-micromolar concentrations, suggesting pfmqo is
indeed potential antimalarial drug target.

doi: 10.3390/genes10060471 
pmcid: pmc6627850
pmid: 31234346  [indexed medline]

